Last reviewed: June 20, 2026
Last updated: June 20, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Ozempic (semaglutide) and Mounjaro (tirzepatide) are both FDA-approved injectable medications for weight loss, yet they work through different biological mechanisms. Tirzepatide activates both GLP-1 and GIP receptors, while semaglutide targets GLP-1 alone, which may explain why clinical trials show tirzepatide producing greater average weight reduction. PlexusDx offers compounded versions of both medications through licensed 503A pharmacies, making personalized GLP-1 therapy accessible without insurance or membership fees.
How Semaglutide and Tirzepatide Work Differently
Semaglutide mimics glucagon-like peptide-1 (GLP-1), a natural hormone that reduces hunger and blood sugar. It works by slowing stomach emptying, signaling fullness to the brain, and improving how the body uses insulin. This single-pathway mechanism has proven effective in reducing body weight by 15–22% over 68 weeks in major clinical trials. Patients typically experience appetite suppression within days to weeks of starting therapy.
Tirzepatide activates both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors simultaneously. This dual-receptor activation enhances weight loss through multiple biological pathways: improved insulin secretion, reduced appetite, and greater metabolic effects on fat and muscle. The SURMOUNT-1 trial demonstrated tirzepatide produced average weight reductions of 21–22% at standard doses, with some cohorts achieving up to 25% reduction. The combination of two pathways may offer an advantage for patients who have plateaued on single-agent therapy.
Clinical Efficacy: Comparing Weight Loss Outcomes
Head-to-head comparisons are limited because Ozempic and Mounjaro entered clinical development at different times with different trial designs. However, indirect evidence suggests tirzepatide achieves numerically greater weight reductions in most patient populations. A 2024 meta-analysis of GLP-1 and GIP trials found dual-receptor agonists produced an average additional 2–4% body weight loss compared to GLP-1 monotherapy at equivalent doses. Individual results vary significantly based on genetics, baseline metabolism, adherence, and lifestyle factors.
For semaglutide, weekly injection doses of 2.4 mg produced sustainable weight loss maintenance in real-world studies, with most patients experiencing results within 3–6 months. Tirzepatide's dosing frequency (also weekly) follows a similar timeline, though some patients report more rapid appetite suppression. Neither medication is inherently "better"—the superior choice depends on your unique metabolic profile, medical history, and response to single versus dual-pathway activation. PlexusDx offers genetic testing through the Precision Peptide Genetic Test to identify which pathway may be most effective for your system.
Cost, Access, and Treatment Flexibility at PlexusDx
Brand-name Ozempic and Mounjaro often cost $900–$1,400 per month without insurance, making them inaccessible for many patients. PlexusDx provides compounded semaglutide starting at $149 per month and compounded tirzepatide injection starting at $249 per month through licensed 503A compounding pharmacies. Both medications are available in all 50 states with no insurance requirement, membership fee, or prior authorization delays. Your dose may need to go up. Your price won't—patients receive flat monthly pricing across all dose levels.
PlexusDx also serves patients seeking oral formulations for needle-free administration. Oral semaglutide begins at $249 per month, while oral tirzepatide starts at $279 per month. Both injectable and oral forms are HSA/FSA eligible, allowing patients to use pretax healthcare savings accounts. The Precision Peptide Genetic Test ($99 add-on after the first month) analyzes 14 metabolic pathways and 49 peptides to predict which compound—or combination—aligns best with your genetic profile.
Side Effects, Safety, and Which Medication Suits You
Both semaglutide and tirzepatide share common side effects: nausea, vomiting, diarrhea, and constipation, most pronounced during dose escalation. Nausea typically occurs in 25–40% of patients and often resolves within 2–4 weeks as the body adapts. Tirzepatide carries a slightly higher incidence of gastrointestinal symptoms in clinical trials, though severity is usually mild to moderate. Serious adverse events (pancreatitis, thyroid concerns) are rare and similar between both compounds.
Semaglutide may be preferred if you have a history of gastrointestinal sensitivity or a family history of medullary thyroid cancer (a relative contraindication). Tirzepatide may offer greater efficacy if you have insulin resistance, prediabetes, or a higher starting BMI, since the GIP pathway enhances insulin action. Patients with baseline kidney or liver dysfunction should discuss dosing adjustments with their PlexusDx clinician. PlexusDx's prescribers review individual health history, contraindications, and previous medication responses to recommend the optimal compound.
Personalized Medicine: The Role of Genetic Testing
Response to GLP-1 and GIP-based therapy varies widely due to genetic variation in peptide pathways. The PlexusDx Precision Peptide Genetic Test examines key genetic variants including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313, which influence how your body processes appetite-regulating hormones. Patients with certain GLP1R variants may respond more robustly to semaglutide, while those with favorable GIPR variants often achieve superior outcomes on tirzepatide or dual-compound therapy.
Genetic insights also predict tolerance and side effect risk. For example, FTO gene variants correlate with baseline metabolic rate and appetite drive; patients with specific FTO alleles may benefit from earlier dose escalation or combination therapy. PlexusDx maps 150+ genetic insights across 14 pathways and 49 peptides, allowing clinicians to move beyond trial-and-error prescribing. The test costs $99 and is completed after your first month of treatment, giving your body time to establish baseline response while your results inform dose optimization.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Is tirzepatide more effective than semaglutide for weight loss?
Clinical trials suggest tirzepatide produces 2–4% greater average weight reduction due to its dual GLP-1 and GIP receptor mechanism. However, individual responses vary significantly. Some patients achieve excellent results on semaglutide alone, while others require tirzepatide's dual pathway. PlexusDx's Precision Peptide Genetic Test helps predict which pathway your genetics favor, guiding the optimal choice from the start.
Why is Mounjaro more expensive than Ozempic?
Brand-name Mounjaro costs more because tirzepatide is newer and patent-protected. At PlexusDx, compounded tirzepatide injection ($249/mo) is only $100 more per month than compounded semaglutide ($149/mo), making the dual-pathway benefit far more affordable than brand pricing. Both remain flat-rate regardless of dose level.
Can I switch from semaglutide to tirzepatide if I'm not seeing results?
Yes. Some patients plateau on single-pathway therapy and respond better to tirzepatide's dual-receptor activation. PlexusDx clinicians can transition you safely, typically within 1–2 weeks. The Precision Peptide Genetic Test can inform whether a switch is likely to yield better outcomes based on your genetic profile.
Are compounded versions of these medications safe?
PlexusDx sources all compounded medications from licensed 503A compounding pharmacies, which operate under strict FDA oversight and state pharmacy board regulations. Compounded semaglutide and tirzepatide are identical to branded molecules and undergo quality testing. They are not FDA-approved drugs themselves, but the active pharmaceutical ingredients meet USP standards.
How does the Precision Peptide Genetic Test help me choose between these medications?
The test identifies genetic variants in GLP1R, GIPR, FTO, MC4R, and 45 other peptide-related genes that predict your response to semaglutide, tirzepatide, or combination therapy. For example, favorable GIPR variants suggest stronger tirzepatide efficacy. The $99 test (after one month of treatment) personalizes your therapy, reducing trial-and-error and optimizing results.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
What Happens If You Inject Wegovy Into a Muscle? Insights for Safe and Effective Use
Is Wegovy FDA Approved for Weight Loss? Exploring the Facts